Spotlight on chronic lymphocytic leukemia: a Pharma Matters report.
London, United Kingdom. In Drugs Today (barc), Jul 2014
Imbruvica (ibrutinib), an oral first-in-class Bruton's tyrosine kinase inhibitor, recently entered the market following accelerated approval in the relapsed/refractory setting, but long-term survival data are currently immature.
Role of Focal Adhesion Tyrosine Kinases in GPVI-Dependent Platelet Activation and Reactive Oxygen Species Formation.
Dublin, Ireland. In Plos One, Dec 2013
To determine the precise location of FAK within the GPVI pathway, we analyzed the effect of PF-228 inhibition in CRP-stimulated platelets in conjunction with immunoprecipitation and pulldown analysis to show that FAK is downstream of Lyn, Spleen tyrosine kinase (Syk), PI3-K and Bruton's tyrosine kinase (Btk) and upstream of Rac1, PLCγ2, Ca2+ release, PKC, Hic-5, NOX1 and αIIbβ3 activation.